Paroxetine exposure during pregnancy and cardiac malformations

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 88, Issue 3, 2010, Pages 175-177

  Scialli, Anthony R ^a,b,c  

^a Tetra Tech Sciences   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c Reproductive Toxicology Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CONGENITAL HEART MALFORMATION; ECHOCARDIOGRAPHY; FIRST TRIMESTER PREGNANCY; HEART ATRIUM SEPTUM DEFECT; HEART RIGHT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HUMAN; MEDICAL LITERATURE; NEWBORN PERIOD; NONHUMAN; NOTE; PREGNANCY; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; RISK; TERATOGENESIS;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; META-ANALYSIS AS TOPIC; MICE; ODDS RATIO; PAROXETINE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; RABBITS; RATS; SEROTONIN UPTAKE INHIBITORS; SPECIES SPECIFICITY; UNCERTAINTY;

EID: 77749246664     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20655     Document Type: Note

References (24)

1. Alwan S, Reefhuis J, Rasmussen SA, et al. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684-2692.
2. Bakker MK, Kerstjens-Frederikse WS, Buys CHCM, et al. 2009. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. Birth Defects Res A Clin Molec Teratol doi 10.1002/bdra.20641.
3. Baldwin JA, Davidson EJ, Pritchard AL, Ridings JE. 1989. The reproductive toxicology of paroxetine. Acta Psychiatr Scand 350(Suppl):37-39.
4. Bar-Oz B, Einarson T, Einarson A, et al. 2007. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther 29:918-926.
5. Bengel D, Murphy DL, Andrews AM, et al. 1998. Altered brain serotonin homeostasis and locomotor insensitivity to 3,4-methylenedioxymethamphetamine ("Ecstasy") in serotonin transporter-deficient mice. Mol Pharmacol 53:649-655.
6. Bérard A, Ramos E, Rey E, et al. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80:18-27.
7. Cole JA, Ephross SA, Cosmatos IS, Walker AM. 2007. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16:1075-1078.
8. Einarson A, Pistelli A, DeSantis M, et al. 2008. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. Am J Psychiatry 165:749-752.
9. Hill AB. 1965. The environment and disease: association or causation? Proc R Soc Med 58:295-300.
10. Källén B, Otterblad Olausson P. 2007. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79:301-308.
11. Lammer EJ, Chen DT, Hoar RM, et al. 1985. Retinoic acid embryopathy. N Engl J Med 313:837-841.
12. Louik C, Lin AE, Werler MM, et al. 2007. First trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675-2683.
13. Moses-Kolko EL, Bogen D, Perel J, et al. 2005. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 293:2372-2383.
14. O'Brien L, Einarson TR, Sarkar M, et al. 2008. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 30:696-701.
15. Pavone LM, Spina A, Rea S, et al. 2009. Serotonin transporter gene deficiency is associated with sudden death of newborn mice through activation of TGF-b1 signalling. J Mol Cell Cardiol 47:691-697.
16. Pedersen LH, Henriksen TB, Vestergaard M, et al. 2009. Selective serotonin inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339:b3569 doi: 10.1136/bmj.b3569.
17. Rayburn WF, Gonzalez CL, Christensen HD, et al. 2000. Effect of antenatal exposure to paroxetine (Paxil) on growth and physical maturation of mice offspring. J Matern Fetal Med 9:136-141.
18. Roguin N, Du Z-D, Barak M, et al. 1995. High prevalence of muscular ventricular septal defect in neonates. J Am Coll Cardiol 26:1545-1548.
19. Sari Y, Zhou FC. 2003. Serotonin and its transporter on proliferation of fetal heart cells. Int J Dev Neurosci 21:417-424.
20. Shuey DL, Sadler TW, Lauder JM, et al. 1992. Serotonin as a regulator of craniofacial morphogenesis: site specific malformations following exposure to serotonin uptake inhibitors. Teratology 46:367-378.
21. Shuey DL, Sadler TW, Tamir H, Lauder JM. 1993. Serotonin and morphogenesis: transient expression of serotonin uptake and binding protein during craniofacial morphogenesis in the mouse. Anat Embryol 187:75-85.
22. Sloot WN, Bowden HC, Yih TD. 2009. In vitro and in vivo reproduction toxicology of 12 monoaminergic re-uptake inhibitors: possible mechanisms of infrequent cardiovascular anomalies. Reprod Toxicol 28: 270-282.
23. Wurst KE, Poole C, Ephross SA, Olshan AF. 2010. First trimester paroxetine use and the prevalence of congenital, specifically cardiac defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol xx:xxx-xxx.
24. Yavarone MS, Shuey DL, Tamir H, et al. 1993. Serotonin and cardiac morphogenesis in the mouse embryo. Teratology 47:573-584.